Expert Review of Cardiovascular Therapy最新文献_第3页

Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study. 肾功能的早期改变似乎不会介导达格列净加西马鲁肽的心血管风险：一项真实世界的观察性假设生成队列研究。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-08-02 DOI: 10.1080/14779072.2026.2713476

Muneera O AlTaweel, Saleh Al Makhloof, Ahmad K AlKhayyal, Jawaher Alrashada, Munirah AlOhaymid, Abdullah Alshahrani, Abdullatif W Alarfaj, Turki A Alqarni, Ghusoon Al Moaibed, Noor M Altharman

{"title":"Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.","authors":"Muneera O AlTaweel, Saleh Al Makhloof, Ahmad K AlKhayyal, Jawaher Alrashada, Munirah AlOhaymid, Abdullah Alshahrani, Abdullatif W Alarfaj, Turki A Alqarni, Ghusoon Al Moaibed, Noor M Altharman","doi":"10.1080/14779072.2026.2713476","DOIUrl":"10.1080/14779072.2026.2713476","url":null,"abstract":"Background: Cardiovascular-kidney-metabolic (CKM) syndrome links heart failure (HF), myocardial infarction (MI), kidney disease, diabetes, and obesity. SGLT2 inhibitors and GLP-1 receptor agonists improve cardiovascular and renal outcomes, but mechanisms underlying combination therapy remain uncertain. We assessed whether early changes in estimated glomerular filtration rate (ΔeGFR) mediate the association between dapagliflozin plus semaglutide and HF/MI-related outcomes.Research design and methods: We conducted a retrospective cohort study of 376 adults prescribed dapagliflozin, with or without semaglutide, at a Saudi tertiary hospital (2020-2024). Inverse probability of treatment weighting and causal mediation analysis evaluated whether ΔeGFR mediated treatment-outcome associations during 90-365days of follow-up.Results: Combination therapy was not associated with a statistically significant difference in recorded HF/MI-related clinical status (adjusted RR 0.787; 95% bootstrap CI 0.320-1.813; p = 0.516). ΔeGFR showed minimal mediation (indirect RR 1.013; 95% CI 0.901-1.165). IPTW analyses yielded similar neutral findings (composite RR 1.12; 95% CI 0.47-2.66).Conclusions: Early ΔeGFR showed little evidence of mediating HF/MI-related risk differences between combination therapy and dapagliflozin alone. Because outcomes were not independently adjudicated, these secondary findings are exploratory. Larger prospective studies are needed.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"743-750"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prioritizing psychological distress reduction during pregnancy for improved cardiovascular health. 优先减少怀孕期间的心理困扰，以改善心血管健康。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-27 DOI: 10.1080/14779072.2026.2707424

Talha Khalid, Muhammad Ramish Irfan, Jeffrey Shi Kai Chan, Danish Iltaf Satti

引用次数: 0

Contemporary role of drug-coated balloons for in-stent restenosis: a critical appraisal of available evidence. 药物包被球囊在支架内再狭窄中的当代作用：对现有证据的关键评价。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-14 DOI: 10.1080/14779072.2026.2703064

Andrea Milzi, Marco Frazzetto, Antonio Landi

引用次数: 0

Molecular and imaging biomarkers in myocardial ischemia/reperfusion injury: from pathogenetic mechanisms to therapeutic targeting. 心肌缺血/再灌注损伤的分子和成像生物标志物：从发病机制到治疗靶向。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-13 DOI: 10.1080/14779072.2026.2703072

Athina Nasoufidou, Marios G Bantidos, Christos Kofos, Nikolaos Stalikas, Andreas Mitsis, Panagiotis Stachteas, Paschalis Karakasis, Maria Fasoula, Barbara Fyntanidou, George Kassimis, Nikolaos Fragakis, Efstratios Karagiannidis

{"title":"Molecular and imaging biomarkers in myocardial ischemia/reperfusion injury: from pathogenetic mechanisms to therapeutic targeting.","authors":"Athina Nasoufidou, Marios G Bantidos, Christos Kofos, Nikolaos Stalikas, Andreas Mitsis, Panagiotis Stachteas, Paschalis Karakasis, Maria Fasoula, Barbara Fyntanidou, George Kassimis, Nikolaos Fragakis, Efstratios Karagiannidis","doi":"10.1080/14779072.2026.2703072","DOIUrl":"10.1080/14779072.2026.2703072","url":null,"abstract":"Introduction: Ischemic heart disease remains a leading cause of morbidity and mortality worldwide despite advances in diagnosis, revascularization, and risk-factor control. Myocardial ischemia/reperfusion (I/R) injury (MIRI) is a multiphase process evolving over minutes to weeks, contributing to infarct expansion, microvascular obstruction, intramyocardial hemorrhage, and adverse ventricular remodeling. High-sensitivity cardiac troponins remain central to diagnosing myocardial necrosis but provide limited mechanistic insight into upstream MIRI processes.Areas covered: For this review, PubMed/MEDLINE and Scopus were searched from inception to May 2026. Established and emerging biomarkers are examined across the I/R continuum, including tissue-derived markers, inflammatory and oxidative-stress mediators, endothelial and neurohormonal biomarkers, remodeling-related proteins, non-coding RNAs, cell-free DNA, extracellular vesicles, metabolomic and proteomic signatures, and multi-omics platforms. Cardiac magnetic resonance and positron emission tomography are also analyzed for tissue characterization and complication detection.Expert opinion: The most realistic role for MIRI biomarkers is selective post-reperfusion phenotyping, as high-sensitivity cardiac troponins will remain the diagnostic anchor in acute myocardial infarction. Their initial clinical value is likely prognostic, refining risk stratification and follow-up intensity. Translation will require standardized assays, harmonized sampling, evidence of incremental value, and prospective demonstration that biomarker-guided decisions improve outcomes, resource allocation, cost-effectiveness, and trial efficiency.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"697-713"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A structured approach to cardiogenic shock: integrating phenotyping, timely circulatory support, and regional care networks. 心源性休克的结构化方法：整合表型，及时循环支持和区域护理网络。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-08-05 DOI: 10.1080/14779072.2026.2713480

Pier Paolo Bocchino, Benedetta De Guidi, Guglielmo Gallone, Simone Frea, Gaetano Maria De Ferrari

引用次数: 0

Improving stress echocardiography-based decision pathways for coronary intervention patients: where can current and previous trials improve real-world practice? 改善基于压力超声心动图的冠状动脉介入患者的决策途径：当前和以前的试验在哪里可以改善现实世界的实践？

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-08-19 DOI: 10.1080/14779072.2026.2713474

Nikolaos P E Kadoglou, Constantinos H Papadopoulos, Evangelos Tatsis, Vasilios Sahpekidis, Nearchos Kasinos, Konstantinos G Papadopoulos, Anastasios Theodosis-Georgilas

{"title":"Improving stress echocardiography-based decision pathways for coronary intervention patients: where can current and previous trials improve real-world practice?","authors":"Nikolaos P E Kadoglou, Constantinos H Papadopoulos, Evangelos Tatsis, Vasilios Sahpekidis, Nearchos Kasinos, Konstantinos G Papadopoulos, Anastasios Theodosis-Georgilas","doi":"10.1080/14779072.2026.2713474","DOIUrl":"10.1080/14779072.2026.2713474","url":null,"abstract":"Introduction: Stress echocardiography (SE) is a widely used noninvasive imaging method to detect myocardial ischemia and assess prognosis in patients with suspected or established coronary artery disease (CAD). However, its results may challenge clinical interpretation and individualized management when technical performance is inadequate.Areas covered: This review summarizes key diagnostic issues regarding SE that affect interpretation and clinical decision pathways for coronary intervention, including: discordance between SE and coronary angiography findings (positive studies with non-obstructive coronaries and negative studies with anatomically significant stenoses), limited myocardial ischemia, and normal wall-motion response with ischemic ECG changes or chest pain. In addition to that, this review discusses issues in specific patient groups like those with small LV cavity/LV hypertrophy, left bundle branch block, extensive baseline wall-motion abnormalities, and atrial fibrillation/arrhythmias. Moreover, we have mentioned recent technological advances like three-dimesion SE and speckle tracking analysis, which have shown promising preliminary results. An extensive literature search was performed in Pubmed and Embase platforms using the appropriate keywords. Unfortunately, the available data are limited and clinical practice is based on operators' experience.Expert opinion: SE remains an operator-dependent technique. In order to improve the objectivity of each study, several steps have been proposed like stress workload adequacy, use of contrast agents, coronary microvascular evaluation commitment, and advocacy of adjunctive methods (atropine infusion, hand-grip).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"729-742"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temporal trends of cardiac implantable electronic devices (CIED) implantation in the Brazilian Public Health System: a 12-year real-world data study. 心脏植入式电子装置（CIED）植入巴西公共卫生系统的时间趋势：一项12年的真实世界数据研究。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-07-01 Epub Date: 2026-02-11 DOI: 10.1080/14779072.2026.2626316

Miriam Allein Zago Marcolino, Rodrigo Antonini Ribeiro, Carisi Anne Polanczyk

{"title":"Temporal trends of cardiac implantable electronic devices (CIED) implantation in the Brazilian Public Health System: a 12-year real-world data study.","authors":"Miriam Allein Zago Marcolino, Rodrigo Antonini Ribeiro, Carisi Anne Polanczyk","doi":"10.1080/14779072.2026.2626316","DOIUrl":"10.1080/14779072.2026.2626316","url":null,"abstract":"Background: Population aging, cardiovascular disease burden, and evolving clinical practices may influence procedure rates, key to health policy planning. This study aimed to describe cardiac implantable electronic devices (CIED) implantation trends in the Brazilian Universal Health System (SUS) over 12 years.Research design and methods: Ecological study using open data on hospital claims (2008-2019) for permanent pacemaker (PM), implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy with pacemaker (CRT-P) or defibrillator (CRT-D) implants. Annual percent changes (APC) with 95% confidence interval (CI) were estimated by linear regression of the logarithm of age and sex standardized implantation rates per million (MM) population (Brazil 2019 population).Results: In total, 216,927 CIED implants were analyzed. Annual implant volume rose from 14,466 to 20,726 (+43.3%). Nonetheless, the standardized rate declined from 108.9 to 98.2/MM (-9.8%), with an APC of -1.2% (95%CI -1.7% to -0.7%). PM and ICD rates were stable, but CRT trends diverged (CRT-D increasing, CRT-P decreasing). Regional analyses showed negative trends for PM and CRT-P, and heterogeneous ICD/CRT-D patterns.Conclusions: Despite increasing volume, standardized CIED implantation rates declined in SUS, especially for PM and CRT-P. Divergent regional trends highlight the need for targeted health policies to ensure equitable access to advanced CIED therapies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"675-683"},"PeriodicalIF":2.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Giant cell myocarditis or sarcoidosis? Time to develop clinically driven non-invasive decision algorithms in inflammatory myocardial diseases: integrating clinical features, biomarkers and multimodality imaging. 巨细胞性心肌炎还是结节病？是时候开发炎症性心肌疾病临床驱动的非侵入性决策算法了：整合临床特征、生物标志物和多模态成像。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-07-01 Epub Date: 2026-06-22 DOI: 10.1080/14779072.2026.2692679

Emanuele Bobbio, Christian L Polte, Entela Bollano, Carsten Tschöpe

引用次数: 0

Life's Essential 8 and its role in cardiovascular health: evolution, evidence, and future directions. 生命的本质及其在心血管健康中的作用：进化、证据和未来方向。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-07-01 Epub Date: 2026-07-09 DOI: 10.1080/14779072.2026.2699875

Abdul Qadeer, Diann Gaalema, Mohanad Albayyaa, Areeba Fareed, Ibrahim Mortada, Brian Katz, Matthew L Mendoza, Afaq Motiwala, Thomas Blackwell, Hani Jneid

{"title":"Life's Essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.","authors":"Abdul Qadeer, Diann Gaalema, Mohanad Albayyaa, Areeba Fareed, Ibrahim Mortada, Brian Katz, Matthew L Mendoza, Afaq Motiwala, Thomas Blackwell, Hani Jneid","doi":"10.1080/14779072.2026.2699875","DOIUrl":"10.1080/14779072.2026.2699875","url":null,"abstract":"Introduction: Cardiovascular disease (CVD) remains the leading global cause of mortality. To improve prevention, the American Heart Association introduced Life's Simple 7 (LS7) in 2010 and updated it to Life's Essential 8 (LE8) in 2022. This review summarizes the development, scientific rationale, predictive validity, and clinical applications of LE8 across diverse populations.Areas covered: A comprehensive search of PubMed, EMBASE, and Scopus through December 2025 identified studies evaluating LS7 and LE8 in U.S. and international cohorts. Evidence from prospective studies, registries, and validation analyses was synthesized to assess prognostic performance. LE8 includes diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose, and blood pressure, each scored on a 0-100 scale. Higher LE8 scores consistently correlate with lower risks of cardiovascular disease, stroke, heart failure, cognitive decline, chronic kidney disease, and all-cause mortality. Findings from NHANES, ARIC, CARDIA, and REGARDS demonstrate strong prognostic validity, while international studies support reproducibility.Expert opinion: LE8 provides a practical framework for cardiovascular health assessment, risk communication, and prevention. Broader implementation may improve population health, although challenges remain, including reliance on self-reported measures and limited integration of psychosocial and environmental determinants of health.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"641-662"},"PeriodicalIF":2.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148381789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prosthetic valve thrombosis: contemporary concepts in diagnosis and management. 人工瓣膜血栓形成：诊断和治疗的现代概念。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-07-01 Epub Date: 2026-07-10 DOI: 10.1080/14779072.2026.2700450

Mohsin Raj Mantoo, Nayani Makkar, Gautam Sharma

{"title":"Prosthetic valve thrombosis: contemporary concepts in diagnosis and management.","authors":"Mohsin Raj Mantoo, Nayani Makkar, Gautam Sharma","doi":"10.1080/14779072.2026.2700450","DOIUrl":"10.1080/14779072.2026.2700450","url":null,"abstract":"Introduction: Prosthetic valve thrombosis (PVT) is a serious, potentially life-threatening complication of mechanical heart valves. Its management remains challenging, with persistent debate regarding the optimal roles of surgery and thrombolytic therapy.Areas covered: This review summarizes contemporary approaches to the diagnosis and management of PVT, based on evidence from observational studies, randomized trials, and major guideline documents. Literature was identified through a PubMed search from inception to March 2026, supplemented by manual review of relevant references. We discuss the role of echocardiography and multimodality imaging in diagnosis, thrombus characterization, and therapeutic decision-making. Evidence comparing surgery and thrombolysis is reviewed, including historical outcomes with conventional thrombolytic regimens and contemporary data using low-dose, slow- or ultraslow-infusion protocols. Recent randomized evidence, including SAFE-PVT and TENET, is considered in the context of current practice.Expert opinion: Management of PVT has shifted from a surgery-dominant paradigm toward individualized, imaging-guided decision-making. In selected patients, standardized fibrinolytic protocols now offer high success rates with acceptable safety, particularly where surgical risk or access is limiting. Surgery remains essential for patients with contraindications to thrombolysis, large thrombus burden, recurrent thrombosis, or failed fibrinolysis.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"609-624"},"PeriodicalIF":2.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0